Saturday, June 11, 2016 12:31:26 PM
My plausible explanation is already in my post. NWBO has claimed that the reasons for the hold were good, yet it's almost a year and still no information. I don't buy the argument that regulators have forbade them from releasing positive information. YET, while there is supposedly good information that would benefit all shareholders, she has increased the amount of value which continues to flow through to Cognate. Despite the hold and cessation of recruitment, the amount of money that flows to Cognate has barely ebbed. Why would that be?
The most damning evidence is the fact that the key assets of NWBO, and us, the shareholders, are the rights to patents, and patents themselves. Those are sheltered off somewhere. I remember when I continually made arguments that such a position was not consistent with good governance, and was told it was done to protect us, the shareholders from an aggressive takeover by Big Pharma. Now we see that if NWBO goes bankrupt, there are no assets to be auctioned off. That means, there will be no companies lining up to bid for the assets of NWBO. Absence of assets means there is no recovery for common stockholders. The company will cease to exist as soon as bankruptcy is filed. Had there been assets safely secured within the company, the stock would be trading much higher. Why? Because the worst case for a company is liquidation value. Imagine, the great potential that DCVAX holds can be had for $68M or less!!
As I noted earlier, if NWBO goes bankrupt, Cognate will continue to exist. With all the money paid, they are rich is cash, and have ALL the manufacturing capacity and knowledge and capability on making DCVAX. Linda would simply find a way to transfer the IP to Cognate through the other controlling companies. Cognate would be public, just in time when DCVAX is approved with $2B valuation. You, me, Woodford and every public shareholder is wiped out, and most done perfectly legally. For all the people who say it is all for the cancer patients, you will be right, but you won't be part of the success.
I hope I am wrong, but the tea leaves tells me that's highly likely to happen.
The most damning evidence is the fact that the key assets of NWBO, and us, the shareholders, are the rights to patents, and patents themselves. Those are sheltered off somewhere. I remember when I continually made arguments that such a position was not consistent with good governance, and was told it was done to protect us, the shareholders from an aggressive takeover by Big Pharma. Now we see that if NWBO goes bankrupt, there are no assets to be auctioned off. That means, there will be no companies lining up to bid for the assets of NWBO. Absence of assets means there is no recovery for common stockholders. The company will cease to exist as soon as bankruptcy is filed. Had there been assets safely secured within the company, the stock would be trading much higher. Why? Because the worst case for a company is liquidation value. Imagine, the great potential that DCVAX holds can be had for $68M or less!!
As I noted earlier, if NWBO goes bankrupt, Cognate will continue to exist. With all the money paid, they are rich is cash, and have ALL the manufacturing capacity and knowledge and capability on making DCVAX. Linda would simply find a way to transfer the IP to Cognate through the other controlling companies. Cognate would be public, just in time when DCVAX is approved with $2B valuation. You, me, Woodford and every public shareholder is wiped out, and most done perfectly legally. For all the people who say it is all for the cancer patients, you will be right, but you won't be part of the success.
I hope I am wrong, but the tea leaves tells me that's highly likely to happen.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
